Regencell Bioscience Holdings Ltd Earnings

Regencell Bioscience Holdings Ltd’s net profit fell -179285.95% since last year same period to $-1.85Mn in the Q4 2024. On a quarterly growth basis, Regencell Bioscience Holdings Ltd has generated -100% fall in its net profits since last 3-months.

Regencell Bioscience Holdings Ltd’s earning per share (EPS) estimates for the current year stand at 0.

Regencell Bioscience Holdings Ltd’s earning per share (EPS) jumped NaN% since last year same period to 0 in the Q3 2025. This indicates that the Regencell Bioscience Holdings Ltd has generated NaN% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Regencell Bioscience Holdings Ltd’s return on assets (ROA) stands at -0.33.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Regencell Bioscience Holdings Ltd’s return on equity (ROE) stands at -0.55.